Quantum BioPharma Overview
- Year Founded
-
1994
- Status
-
Public
- Employees
-
7
- Stock Symbol
-
QNTM
- Investments
-
7
- Share Price
-
$1.28
- (As of Friday Closing)
Quantum BioPharma General Information
Description
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
Contact Information
Website
www.quantumbiopharma.comCorporate Office
- 1 Adelaide Street East
- Suite 801
- Toronto, Ontario M5C 2V9
- Canada
Corporate Office
- 1 Adelaide Street East
- Suite 801
- Toronto, Ontario M5C 2V9
- Canada
Quantum BioPharma Timeline
Quantum BioPharma Stock Performance
As of 20-Nov-2026, Quantum BioPharma’s stock price is $1.28. Its current market cap is $11.1M with 8.59M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.28 | $1.42 | $1.26 - $12.42 | $11.1M | 8.59M | 149K | -$3.19 |
Quantum BioPharma Financials Summary
As of 30-Sep-2026, Quantum BioPharma has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 24,366 | 29,790 | (222) | 31,604 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (20,045) | (26,029) | (14,950) | (16,510) |
| Net Income | (20,137) | (26,175) | (14,203) | (17,902) |
| Total Assets | 17,331 | 11,161 | 17,119 | 17,475 |
| Total Debt | 924 | 1,876 | 825 | 339 |
Quantum BioPharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Quantum BioPharma Comparisons
Industry
Financing
Details
Quantum BioPharma Competitors (2)
One of Quantum BioPharma’s 2 competitors is Avicanna, a Formerly VC-backed company based in Toronto, Canada.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Avicanna | Formerly VC-backed | Toronto, Canada | ||||
| Tetra Bio-Pharma | Corporation | Orleans, Canada |
Quantum BioPharma Signals
Quantum BioPharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Quantum BioPharma Investments & Acquisitions (7)
Quantum BioPharma’s most recent deal was a Corporate with Unbuzzd Wellness for . The deal was made on 09-Aug-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Unbuzzd Wellness | 09-Aug-2024 | Corporate | Other Consumer Non-Durables | ||
| Lucid Psycheceuticals | 21-Sep-2021 | Merger/Acquisition | Drug Discovery | ||
| Prismic Pharmaceuticals | 28-Jun-2019 | Merger/Acquisition | Drug Discovery | ||
| FSD Jamaica | 13-Sep-2018 | Joint Venture | Other Pharmaceuticals and Biotechnology | ||
| Cannara Biotech | 19-Jul-2018 | Corporate | Cultivation |
Quantum BioPharma ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Quantum BioPharma Exits (1)
Quantum BioPharma’s most recent exit was on 19-Jul-2018 from Cannara Biotech. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Cannara Biotech | 19-Jul-2018 | Completed |
|
Quantum BioPharma Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Lucid Psycheceuticals | Toronto, Canada | 2020 | |
| FSD Atlantic Pharma | St. John's, Canada | 2018 |
Quantum BioPharma FAQs
-
When was Quantum BioPharma founded?
Quantum BioPharma was founded in 1994.
-
Where is Quantum BioPharma headquartered?
Quantum BioPharma is headquartered in Toronto, Canada.
-
What is the size of Quantum BioPharma?
Quantum BioPharma has 7 total employees.
-
What industry is Quantum BioPharma in?
Quantum BioPharma’s primary industry is Drug Discovery.
-
Is Quantum BioPharma a private or public company?
Quantum BioPharma is a Public company.
-
What is Quantum BioPharma’s stock symbol?
The ticker symbol for Quantum BioPharma is QNTM.
-
What is the current stock price of Quantum BioPharma?
As of 20-Nov-2026 the stock price of Quantum BioPharma is $1.28.
-
What is the current market cap of Quantum BioPharma?
The current market capitalization of Quantum BioPharma is $11.1M.
-
Who are Quantum BioPharma’s competitors?
Avicanna and Tetra Bio-Pharma are competitors of Quantum BioPharma.
-
What is Quantum BioPharma’s annual earnings per share (EPS)?
Quantum BioPharma’s EPS for 12 months was -$3.19.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process